CST Announces Pilot Study to Evaluate PhosphoScan™ Platform for Kinase Inhibitor Phosphoproteomic Profiling
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Cell Signaling Technology, Inc. (CST) has announced an agreement with Novartis under which a pilot study was performed using CST's PhosphoScan™ technology to identify phosphorylation sites and prospective biomarkers of protein kinase targets.
CST's PhosphoScan™ phospho-proteomics technology enables the determination of cellular kinase phospho-profiles (Phospho-Signatures™) and is based on patent-pending methodologies combining immunoaffinity purification and mass spectroscopy.
The PhosphoScan™ technology was described in the journal, Nature Biotechnology (Rush J. et al, Nat. Biotechnol. 23, 94-101 (2005)). The phospho-profiles discovered with PhosphoScan™ may enable biomarker assays for target validation and kinase inhibitor clinical development.
"Our PhosphoScan™ pilot with Novartis was a great opportunity to demonstrate the utility and value of cellular phospho-profiles and modulation of these by kinase inhibitors," said Christopher Bunker, CST's Director of Business Development.
"We are able to use PhosphoScan™ to deliver focused, in-depth Phospho-Signatures™ of disease cells and tissues and provide the basis for kinase biomarkers. CST superiority in antibody and immunoassay development is fully integrated with PhosphoScan™, and this can enable CST to translate PhosphoScan™ discoveries into validated biomarker assays."
CST's PhosphoScan™ phospho-proteomics technology enables the determination of cellular kinase phospho-profiles (Phospho-Signatures™) and is based on patent-pending methodologies combining immunoaffinity purification and mass spectroscopy.
The PhosphoScan™ technology was described in the journal, Nature Biotechnology (Rush J. et al, Nat. Biotechnol. 23, 94-101 (2005)). The phospho-profiles discovered with PhosphoScan™ may enable biomarker assays for target validation and kinase inhibitor clinical development.
"Our PhosphoScan™ pilot with Novartis was a great opportunity to demonstrate the utility and value of cellular phospho-profiles and modulation of these by kinase inhibitors," said Christopher Bunker, CST's Director of Business Development.
"We are able to use PhosphoScan™ to deliver focused, in-depth Phospho-Signatures™ of disease cells and tissues and provide the basis for kinase biomarkers. CST superiority in antibody and immunoassay development is fully integrated with PhosphoScan™, and this can enable CST to translate PhosphoScan™ discoveries into validated biomarker assays."
